These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37448522)

  • 1. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
    Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
    Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
    Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
    Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
    Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
    Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
    Ünal Ç; Özmen T; İlgün AS; Ordu Ç; Özkurt E; Ak N; Alço G; Erdoğan İyigün Z; Kurt S; Duymaz T; Öztürk MA; Elbüken Çelebi F; Yararbaş K; Soybir G; Aktepe F; Özmen V
    Breast Cancer (Dove Med Press); 2023; 15():659-669. PubMed ID: 37674872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria.
    Zekri J; Al-Foheidi M; Alata M; Zabani R; Rasmy A
    Breast Care (Basel); 2020 Dec; 15(6):642-647. PubMed ID: 33447239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Orucevic A; Bell JL; McNabb AP; Heidel RE
    Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS).
    Casasanta N; Patel R; Raymond S; Kier MW; Blanter J; Sohval S; Hovstadius M; Wu C; Zimmerman B; Cascetta K; Bagiella E; Tiersten A
    Clin Breast Cancer; 2024 Oct; 24(7):585-596. PubMed ID: 38971641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
    Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
    Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.
    Braun M; Kriegmair A; Szeterlak N; Andrulat A; Schrodi S; Kriner M; Hanusch C; Hamann M; Stoetzer O; Pölcher M
    Breast Care (Basel); 2022 Jun; 17(3):288-295. PubMed ID: 35957951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
    Özmen V; Çakar B; Gökmen E; Özdoğan M; Güler N; Uras C; Ok E; Demircan O; Işıkdoğan A; Saip P
    Eur J Breast Health; 2019 Jul; 15(3):183-190. PubMed ID: 31312795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study.
    Nam G; Singh K; Lopresti ML; Ouseph MM; Wang LJ; Wang Y
    Technol Cancer Res Treat; 2021; 20():15330338211035037. PubMed ID: 34696631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
    Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
    Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score.
    Al-Zawi ASA; Yin SL; Aladili Z
    Contemp Oncol (Pozn); 2022; 26(2):139-143. PubMed ID: 35903213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
    Rizki H; Hillyar C; Abbassi O; Miles-Dua S
    Cureus; 2020 Mar; 12(3):e7269. PubMed ID: 32195072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.